Niacin Extended-Release Tablets, USP 500mg, Rx Only, 90 Tablets per bottle, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191(U.T. of D & NH), INDIA, NDC 47335-539-81.

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Recall #: D-0270-2024
Affected scope: 15,768 bottles
Initiated: January 18, 2024

Compiled from official public sources by the publisher. · Updated September 2026

Sun Pharmaceutical Industries INC recalled Niacin Extended-Release Tablets, USP 500mg, Rx Only, 90 Tablets per bottle, Distributed b… - a moderate-severity action.

Niacin Extended-Release Tablets, USP 500mg, Rx Only, 90 Tablets per bottle, Distributed b… was recalled by Sun Pharmaceutical Industries INC in January 31, 2024. Reason: CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equi…. Check the official notice for the remedy. Verify recall #D-0270-2024 with the FDA Drug before acting.

The recall

Sun Pharmaceutical Industries INC issued this moderate-severity FDA Drug recall-CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equi….

Moderate
severity level: Class II
classification: January 31, 2024
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0270-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Niacin Extended-Release Tablets, USP 500mg, Rx Only, 90 Tablets per bottle, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191(U.T. of D & NH), INDIA, NDC 47335-539-81.

Reason for recall

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Completed
Recall number	D-0270-2024
Date reported	January 31, 2024
Date initiated	January 18, 2024
Recalling firm	Sun Pharmaceutical Industries INC
Firm location	Princeton, NJ
Affected scope	15,768 bottles
Distribution	Nationwide in the USA

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0270-2024) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on January 31, 2024. Severity: Moderate. Recall number: D-0270-2024.

Where was the recalled product distributed? ▼

Distribution: Nationwide in the USA.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

Vasopressin 2 Unit/2 mL in 0.9% Sodium Ch… 2024-01-31 Fosaprepitant for Injection 150 mg per vi… 2024-01-31 R&B Chocolate Chips Croissant Twist 2024-01-31 RTB MIXED DANISH Variety 2024-01-31

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Benzonatate Capsules, USP, 100 mg, 100 Ca… 2024-01-31 Bleomycin for Injection, USP, 15 units pe… 2024-01-31 iFIT Recalls NordicTrack 50 LB iSelect Vo… 2024-02-01 Budesonide Extended-Release Tablets, 9 mg… 2024-02-07

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported January 31, 2024. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026